Stemline Therapeutics (NASDAQ:STML) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday.
According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “
Several other brokerages have also commented on STML. Cowen reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. HC Wainwright reaffirmed a “buy” rating and set a $34.00 price target on shares of Stemline Therapeutics in a research report on Tuesday, September 12th. BidaskClub lowered shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, ValuEngine raised shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $33.75.
In other news, COO Kenneth Hoberman sold 11,983 shares of the stock in a transaction on Monday, December 18th. The shares were sold at an average price of $14.18, for a total value of $169,918.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 16.70% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the company. Voya Investment Management LLC acquired a new stake in shares of Stemline Therapeutics in the second quarter worth $102,000. Nationwide Fund Advisors grew its holdings in Stemline Therapeutics by 7.2% during the 2nd quarter. Nationwide Fund Advisors now owns 12,755 shares of the biopharmaceutical company’s stock valued at $117,000 after purchasing an additional 855 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in Stemline Therapeutics during the 2nd quarter valued at $147,000. Alliancebernstein L.P. acquired a new stake in Stemline Therapeutics during the 2nd quarter valued at $178,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Stemline Therapeutics by 40.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,279 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 5,522 shares in the last quarter. 50.24% of the stock is owned by institutional investors.
WARNING: “Zacks Investment Research Upgrades Stemline Therapeutics (STML) to “Hold”” was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/01/05/zacks-investment-research-upgrades-stemline-therapeutics-stml-to-hold.html.
About Stemline Therapeutics
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.